Cologne based Cevec specialises in producing tailor-made recombinant glycoproteins and gene therapy vectors. Now it has announced a breakthrough in their adenoviral vectors used in Gene Therapy.
The increasing number of gene therapy-based discovery programs in the biotech and pharma industry is driving a greater need for the scalable production of gene therapy vectors.
Vectors are needed to transport a desired gene to the patient, and simple viruses are a popular choice to do so.
Examples of biotechs which have trials using Adeno-assosciated viral vectors include Lysogene (working on the rare disease San Filippo syndrome with adeno-associated viral vectors), GenSight (looking to ‘cure blindness’ using adenoviral vectors) and Theravectys (using lentiviral vectors for vaccines against Leukemia).
However, the problem is production of these vectors to comply with GMP standards and to ensure their safety (as viral vectors) by rendering them incapable of self-replication, to prevent them from transfecting cells outside the targeted tissue area.